Clinical Trial Update: Tivozanib + Gemcitabine in Metastatic RCC [Phase 2]

View source ↗

Summary

A Phase 2 trial of tivozanib plus gemcitabine in metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Tivozanib (tivozanib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Renal Cell Carcinoma | Phase 2 | Status: WITHDRAWN